Publication date: Available online 26 October 2026 Source: The Journal of Pharmacology and Experimental Therapeutics Author(s): Jianan Lin, Chuying Wu, Huida Zheng, Pengcheng Wang, Kai Ye
TFAP4 Promotes Glycolysis and Chemoresistance via Transcriptional Activation of PSAT1 in Colon Cancer. // The Journal of Pharmacology and Experimental Therapeutics. – URL: https://www.sciencedirect.com/science/article/pii/S0022356526012528?dgcid=rss_sd_all
TFAP4 Promotes Glycolysis and Chemoresistance via Transcriptional Activation of PSAT1 in Colon Cancer. The Journal of Pharmacology and Experimental Therapeutics. https://www.sciencedirect.com/science/article/pii/S0022356526012528?dgcid=rss_sd_all
“TFAP4 Promotes Glycolysis and Chemoresistance via Transcriptional Activation of PSAT1 in Colon Cancer.” The Journal of Pharmacology and Experimental Therapeutics.
@article{article32457,
title = {TFAP4 Promotes Glycolysis and Chemoresistance via Transcriptional Activation of PSAT1 in Colon Cancer},
journal = {The Journal of Pharmacology and Experimental Therapeutics},
url = {https://www.sciencedirect.com/science/article/pii/S0022356526012528?dgcid=rss_sd_all}
}
Acta Pharmacologica Sinica, Published online: 16 November 2026; doi:10.1038/s41401-026-01953-z IRAK4 inhibitor DW18134 ameliorates diffuse large B-cell lymphoma in combination with ibrutinib and overcomes acquired resistance to ibrutinib
Acta Pharmacologica Sinica, Published online: 16 November 2026; doi:10.1038/s41401-026-01958-8 Artificial intelligence aids multi-omics data integration in cancer drug discovery and development: from targets to drug synergy
Nature Reviews Drug Discovery, Published online: 13 November 2026; doi:10.1038/d41573-026-00179-2 The NIH’s P. J. Brooks discusses the challenges and opportunities ahead for gene therapies and gene editing for diseases of no commercial interest.
Nature Reviews Drug Discovery, Published online: 13 November 2026; doi:10.1038/d41573-026-00181-8 Merck and Moderna’s intismeran autogene succeeded in a landmark melanoma trial, but the oncology community still has more questions than...